Z-ORn(z)-osu

Catalog No. :
ACQNOS174
CAS No. :
90970-61-9
Molecular Formula :
C25H27N3O8
Molecular Weight :
497.50

IUPAC Name:2,5-dioxopyrrolidin-1-yl (S)-2,5-bis(((benzyloxy)carbonyl)amino)pentanoate

Z-ORn(z)-osu structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g94%$78.00Login to see priceInquiryInquiry
5g94%$253.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameZ-ORn(z)-osu
IUPAC Name2,5-dioxopyrrolidin-1-yl (S)-2,5-bis(((benzyloxy)carbonyl)amino)pentanoate
MDL No.MFCD00237359
Molecular FormulaC25H27N3O8
Molecular Weight497.50
SMILESO=C(OCC1=CC=CC=C1)NCCC[C@@H](C(ON2C(CCC2=O)=O)=O)NC(OCC3=CC=CC=C3)=O
InChI KeyPGMBMJCWSOQENR-FQEVSTJZSA-N
SynonymNα,δ-Bis-Z-L-ornithineN-hydroxysuccinimide ester≥ 98% (TLC);Z-L-Orn(Z)-OSu;Z-ORNITHINE(Z)-OSU;Z-ORN(Z)-OSU;N-ALPHA,N-DELTA-BIS-Z-L-ORNITHINE N-HYDROXYSUCCINIMIDE ESTER;N-alpha,delta-Bis-Z-L-ornithine N-hydroxysuccinimide ester;Nα,δ-Bis-Z-L-ornithine N-hydroxysuccinimide ester;CBZ-ORN(Z)-OSU
CAS No.90970-61-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACQNOS174 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACPOQL635 route compound structure diagram
    ACPOQL6356066-82-6 In Stock
  4. Then
  5. ACQNOS174 route product structure diagram
    ACQNOS17490970-61-9
Inquiry

2. ACQNOS174 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQNOS174 route product structure diagram
    ACQNOS17490970-61-9
Inquiry

Comments (0)